Leaving This Website

You are leaving this page. This link will take you to a website where our Terms of Use do not apply. EMD Serono, a business of Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.++

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.

OUR TRIALS

Welcome to our clinical trial platform informing about our research of tepotinib, an investigational, highly selective oral MET kinase inhibitor that is designed to inhibit the oncogenic signaling caused by MET (gene) alterations.

Tepotinib is under clinical investigation in several countries of the world. Safety and efficacy of tepotinib have to be investigated following the respective local regulations and laws. There is no guarantee that tepotinib will be approved in the sought-after indication by the competent health authority in your country.


Find out more about our trials below

VISION


LUNG

ADVANCED
METASTATIC

PHASE
2

MONOTHERAPY

A phase 2, single-arm, multi-cohort clinical trial investigating tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET alterations.

ClinicalTrials.gov: NCT02864992

Location: Asia, Europe, North America

Status:

NOW ENROLLING

 

 

INSIGHT 2


LUNG

ADVANCED
METASTATIC

PHASE
2

COMBINATION
THERAPY

A phase 2 clinical trial to investigate tepotinib combined with osimertinib in patients with EGFR-TKI resistant, MET amplified non-small cell lung cancer (NSCLC).

ClinicalTrials.gov: NCT03940703

Location: Asia, Europe, North America

Status:

NOW ENROLLING

 

 

Learn More About

Clinical Trials